The rise of antimicrobial resistance (AMR) has necessitated ongoing initiatives to offset the global threat and promote innovation, with financial incentives being key to spurring new antibacterial drug development
Dr Bill Love, Chief Scientific Officer at Destiny Pharma, writes “The rise of antimicrobial resistance (AMR) has necessitated ongoing initiatives to offset the global threat and promote innovation, with financial incentives being key to spurring new antibacterial drug development”.
To read the full article, please click here
This article is taken from European Biopharmaceutical Review April 2022, pages 31-33. © Samedan Ltd